These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19187071)

  • 21. Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.
    Doward LC; Dietz B; Wilburn J; McKenna SP; Bhor M; Rajagopalan R
    AIDS Read; 2008 May; 18(5):242-6, 252-6, 262-4. PubMed ID: 18589480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency, activation, and coreceptor expression of lymphocytes in human immunodeficiency virus/hepatitis C virus co-infected patients in China.
    Shi W; Zhang Z; Zhang M; Liu J; Jiang Y; Wang Y; Jin X; Han X; Shang H
    Jpn J Infect Dis; 2009 Jul; 62(4):284-8. PubMed ID: 19628906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coronary heart disease in people infected with HIV.
    Malvestutto CD; Aberg JA
    Cleve Clin J Med; 2010 Aug; 77(8):547-56. PubMed ID: 20682517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus and metabolic disturbances.
    Nuñez M
    IAPAC Mon; 2005 Jul; 11(7):216-7. PubMed ID: 16676426
    [No Abstract]   [Full Text] [Related]  

  • 25. [Metabolic alterations, AIDS and vascular disease].
    Betancor León P
    An Med Interna; 2007 Apr; 24(4):157-9. PubMed ID: 17867897
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiretroviral nephrotoxicities.
    Atta MG; Deray G; Lucas GM
    Semin Nephrol; 2008 Nov; 28(6):563-75. PubMed ID: 19013327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution.
    Balasubramanyam A; Sekhar RV
    Res Initiat Treat Action; 2006; 12(1):5-11. PubMed ID: 17153230
    [No Abstract]   [Full Text] [Related]  

  • 29. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions.
    Soriano V; Rivas P; Nuñez M
    Clin Infect Dis; 2008 Dec; 47(11):1486-9. PubMed ID: 18937578
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV/hepatitis co-infection.
    Rockstroh J
    J HIV Ther; 2007 Mar; 12(1):1. PubMed ID: 17589388
    [No Abstract]   [Full Text] [Related]  

  • 31. De-"Liver"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity.
    Cooper CL
    J Infect Dis; 2007 Sep; 196(5):656-8. PubMed ID: 17674305
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis C and diabetes: the inevitable coincidence?
    Lonardo A; Adinolfi LE; Petta S; Craxì A; Loria P
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):293-308. PubMed ID: 19344243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular disease in HIV infection.
    Sánchez-Torres RJ; García-Palmieri MR
    P R Health Sci J; 2006 Sep; 25(3):249-54. PubMed ID: 17203795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: a marker for nonliver, non-opportunistic disease mortality.
    Wyles DL
    Clin Infect Dis; 2008 Dec; 47(11):1476-8. PubMed ID: 18959495
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease.
    Berzsenyi MD; Bowden DS; Roberts SK; Revill PA
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1407-10. PubMed ID: 19702909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-infections. Hepatitis C virus--some background information.
    TreatmentUpdate; 2008; 20(3):5-8. PubMed ID: 18661654
    [No Abstract]   [Full Text] [Related]  

  • 39. Metabolic abnormalities in chronic hepatitis C. Introduction.
    Capeau J; Gharakanian S; Younossi ZM
    Liver Int; 2009 Mar; 29 Suppl 2():1-2. PubMed ID: 19187072
    [No Abstract]   [Full Text] [Related]  

  • 40. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options.
    Tebas P
    J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S86-92. PubMed ID: 18725817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.